User:Mr. Ibrahem/Baricitinib

Baricitinib, sold under the brand name Olumiant among others, is a medication used to treat rheumatoid arthritis (RA) and COVID-19. In RA it is used in those who are not controlled by tumor necrosis factor (TNF) inhibitors. In COVID-19 it is used in those with severe disease. It is taken by mouth.

Common side effects include nausea, upper respiratory tract infection, shingles, and herpes simplex. Other side effects may include severe infections, lymphoma, blood clots, GI perforation, and liver problems. There is no data one use in pregnancy, though use in other animals may result in harm to the baby. It is an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.

Baricitinib was approved for medical use in the Europe in 2017 and the United States in 2018. In the United Kingdom 28 tablets of 2 mg costs the NHS about £800 as of 2021. This amount in the United States costs about 2,300 USD.